

Lupin receives FDA approval for generic Flagyl & Vibra-Tabs tablets

14 September 2017 | News

Flagyl Tablets had US sales of USD 44.1 million (IMS MAT June 2017) and Doxycycline Hyclate Tablet USP, 100 mg had US sales of USD 149.9 million (IMS MAT June 2017)



Pharma Major Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg and Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC's Flagyl Tablets, 250 mg and 500 mg and Pfizer Inc.'s Vibra-Tabs 100 mg respectively.

Lupin's Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of G.D. Searle LLC's Flagyl Tablets, 250 mg and 500 mg and indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.

Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.'s Vibra-Tabs 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Flagyl Tablets had US sales of USD 44.1 million (IMS MAT June 2017) and Doxycycline Hyclate Tablet USP, 100 mg had US sales of USD 149.9 million (IMS MAT June 2017).